Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of GS-2426 in Advanced MTAP-Deleted Solid Tumors
NCT07601243Phase 1Recruiting
- Sponsor
- Gilead Sciences
- Start
- Jun 2026
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of GS-2426 in solid tumor, sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAE) up to 105 weeks and Percentage of Participants Experiencing Clinical Laboratory Abnormalities up to 105 weeks. Started Jun 2026; status: recruiting.
02
Drugs
GS-2426
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07601243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07601243.